Show simple item record

dc.contributor.authorMohan, Sumitra
dc.contributor.authorChemi, Francesca
dc.contributor.authorBrady, Ged
dc.date.accessioned2017-10-23T19:12:45Z
dc.date.available2017-10-23T19:12:45Z
dc.date.issued2017-08
dc.identifier.citationChallenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer. 2017, 6 (4):454-472 Transl Lung Cancer Resen
dc.identifier.issn2218-6751
dc.identifier.pmid28904889
dc.identifier.doi10.21037/tlcr.2017.06.04
dc.identifier.urihttp://hdl.handle.net/10541/620609
dc.description.abstractSince blood borne circulating tumour cells (CTCs) initially shed from the primary tumour can seed and initiate metastasis at distant sites a better understanding of the biology of CTCs and their dissemination could provide valuable information that could guide therapeutic intervention and real time monitoring of disease progression. Although CTC enumeration has provided a reliable prognostic readout for a number of cancers, including lung cancer, the precise clinical utility of CTCs remains to be established. The rarity of CTCs together with the vanishingly small amounts of nucleic acids present in a single cell as well as cell to cell heterogeneity has stimulated the development of a wide range of powerful cellular and molecular methodologies applied to CTCs. These technical developments are now enabling researchers to focus on understanding the biology of CTCs and their clinical utility as a predictive and pharmacodynamics markers. This review summarises recent advances in the field of CTC research with focus on technical and biological challenges as well the progress made towards clinical utility of characterisation of CTCs with emphasis on studies in lung cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Translational lung cancer researchen
dc.titleChallenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, CRUK Manchester Institute, University of Manchester, Manchesteren
dc.identifier.journalTranslational Lung Cancer Researchen
html.description.abstractSince blood borne circulating tumour cells (CTCs) initially shed from the primary tumour can seed and initiate metastasis at distant sites a better understanding of the biology of CTCs and their dissemination could provide valuable information that could guide therapeutic intervention and real time monitoring of disease progression. Although CTC enumeration has provided a reliable prognostic readout for a number of cancers, including lung cancer, the precise clinical utility of CTCs remains to be established. The rarity of CTCs together with the vanishingly small amounts of nucleic acids present in a single cell as well as cell to cell heterogeneity has stimulated the development of a wide range of powerful cellular and molecular methodologies applied to CTCs. These technical developments are now enabling researchers to focus on understanding the biology of CTCs and their clinical utility as a predictive and pharmacodynamics markers. This review summarises recent advances in the field of CTC research with focus on technical and biological challenges as well the progress made towards clinical utility of characterisation of CTCs with emphasis on studies in lung cancer.


This item appears in the following Collection(s)

Show simple item record